Trade Report: The 634 Shares of Sanofi (SNY) are sold by Essex Financial Services Inc.

The 634 Shares of Sanofi (SNY) are sold by Essex Financial Services Inc.

Essex Financial Services Inc. lowered its stake in shares of Sanofi (NYSE:SNY) by 5.5% during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 10,940 shares of the company’s stock after selling 634 shares during the period. Essex Financial Services Inc.’s holdings in Sanofi were worth $458,000 as of its most recent SEC filing.

Other institutional investors have also added to or reduced their stakes in the company. Rehmann Capital Advisory Group increased its stake in shares of Sanofi by 0.5% in the second quarter. Rehmann Capital Advisory Group now owns 5,571 shares of the company’s stock valued at $233,000 after buying an additional 26 shares during the period. First Manhattan Co. increased its stake in shares of Sanofi by 0.6% in the second quarter. First Manhattan Co. now owns 19,281 shares of the company’s stock valued at $806,000 after buying an additional 113 shares during the period. JFS Wealth Advisors LLC increased its stake in shares of Sanofi by 3.5% in the second quarter. JFS Wealth Advisors LLC now owns 3,961 shares of the company’s stock valued at $166,000 after buying an additional 134 shares during the period. Ladenburg Thalmann Financial Services Inc. increased its stake in shares of Sanofi by 0.6% in the first quarter. Ladenburg Thalmann Financial Services Inc. now owns 33,104 shares of the company’s stock valued at $1,329,000 after buying an additional 213 shares during the period. Finally, 1st Global Advisors Inc. increased its stake in shares of Sanofi by 1.9% in the second quarter. 1st Global Advisors Inc. now owns 25,710 shares of the company’s stock valued at $1,076,000 after buying an additional 479 shares during the period. Hedge funds and other institutional investors own 9.37% of the company’s stock.

Shares of Sanofi (NYSE:SNY) traded down 1.06% during midday trading on Monday, hitting $37.35. 2,024,179 shares of the stock were exchanged. The firm’s 50-day moving average is $38.61 and its 200-day moving average is $40.38. The stock has a market cap of $96.14 billion, a price-to-earnings ratio of 20.85 and a beta of 0.98. Sanofi has a 12 month low of $37.20 and a 12 month high of $51.88.

Several equities research analysts recently weighed in on the stock. TheStreet raised shares of Sanofi from a “hold” rating to a “buy” rating in a research report on Wednesday, July 27th. Zacks Investment Research raised shares of Sanofi from a “sell” rating to a “hold” rating in a research report on Monday, July 25th. Berenberg Bank reissued a “hold” rating and set a $93.00 price target on shares of Sanofi in a research report on Monday, August 15th. BNP Paribas raised shares of Sanofi from an “underperform” rating to a “neutral” rating in a research report on Tuesday, September 13th. Finally, JPMorgan Chase & Co. reissued an “underweight” rating on shares of Sanofi in a research report on Thursday, September 15th. Three analysts have rated the stock with a sell rating, nine have issued a hold rating and five have assigned a buy rating to the company’s stock. Sanofi presently has a consensus rating of “Hold” and a consensus price target of $60.50.

Sanofi Company Profile

Sanofi, formerly Sanofi-Aventis, is a healthcare company engaged in the research, development, manufacture and marketing of therapeutic solutions. The Company operates through three segments: Pharmaceuticals, Human Vaccines (Vaccines) and Animal Health. The Pharmaceuticals segment consists of research, development, production and marketing of medicines, including those originating from Genzyme Corporation.

Related posts

Leave a Comment